Dr Laura Donnelly

Laura is a Commercialisation Manager in the Technology Transfer Team where she works to commercialise technologies from across the life sciences.

She has experience in identifying, managing, developing and commercialising a range of life sciences IP. She has particular experience of working in the fields of stem cell research, medical devices and drug discovery and has worked on a variety of deals including licenses to spin-out comapnies and multi-national corporations. Laura helped support NoBACZ Healthcare, a wound care company, raise >£3 million since 2020. Laura has also supported multiple projects under development with Apollo Therapeutics and helped manage the University of Cambridge – GSK Open Innovation Drug Discovery Initiative at the Stevenage Bioscience Catalyst. As part of her role at Cambridge Enterprise, Laura spent five months on secondment as a Business Development Manager at one of Cambridge Enterprise’s spin-out companies, Cambridge Epigenetix.

Before joining Cambridge Enterprise, Laura worked as a postdoctoral researcher at the University of Manchester, studying the regulation of cardiac function and disease by cell signalling pathways. Laura obtained a PhD in Biochemistry from the University of Manchester and a BSc in Biochemistry from the University of York.

Laura joined Cambridge Enterprise in 2011.